Pramlintide
A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
AstraZeneca · Phase 2 · Completed · Enrollment 177
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo and Metreleptin | n/r | n/r | n/r | n/r |
| Pramlintide Acetate and Placebo | n/r | n/r | n/r | n/r |
| Pramlintide Acetate and Metreleptin | n/r | n/r | n/r | n/r |
| Lead-In Period | n/r | n/r | n/r | n/r |
Not shown
- Placebo and Metreleptin: endpoint not reported
- Pramlintide Acetate and Placebo: endpoint not reported
- Pramlintide Acetate and Metreleptin: endpoint not reported
- Lead-In Period: endpoint not reported